Brief: Indaptus Therapeutics Reports Encouraging New Safety Data For Decoy20 Clinical Program Company Expands Enrollment Of Patients On Weekly Dosing At Two Different Doses

Indaptus Therapeutics

05/09/2024 13:40

Indaptus Therapeutics Inc  INDP.O :
    * INDAPTUS THERAPEUTICS REPORTS ENCOURAGING NEW SAFETY DATA
FOR
DECOY20 CLINICAL PROGRAM; COMPANY EXPANDS ENROLLMENT OF PATIENTS
ON WEEKLY DOSING AT TWO DIFFERENT DOSES
    * INDAPTUS THERAPEUTICS INC: CONTINUE DOSING ADDITIONAL
PATIENTS
AT LOWER DECOY20 DOSE ON A WEEKLY SCHEDULE
    * INDAPTUS THERAPEUTICS INC: INITIATE DOSING PATIENTS AT
HIGHER
DECOY20 DOSE ON A WEEKLY SCHEDULE
    * INDAPTUS THERAPEUTICS INC: SAFETY PROFILE BEING OBSERVED
TO DATE
CONTINUES TO BE CONSISTENT WITH DECOY20'S MECHANISM OF ACTION

Source text for Eikon:  ID:nGNX3CJbSz 
Further company coverage:  INDP.O